Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice

Neurobiology of Disease

Volumn 36, Issue 3, 2009, Pages 413-420

  Li, Mei ^a   Huang, Yong ^b   Ma, Aye Aye K ^a   Lin, Emil ^b   Diamond, Marc I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; HUNTINGTIN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN WEIGHT; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG TARGETING; EXON; FEMALE; HUNTINGTON CHOREA; LIFESPAN; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; SINGLE DRUG DOSE;

AMIDES; ANIMALS; BRAIN; CELL COUNT; DISEASE MODELS, ANIMAL; DYSKINESIAS; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUNTINGTON DISEASE; LONGEVITY; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PYRIDINES; RANDOM ALLOCATION; RHO-ASSOCIATED KINASES; TIME FACTORS;

EID: 70350348368     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.06.011     Document Type: Article

References (38)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group, 1993. Cell. 72, 971-83.
2. Apostol B.L., et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5950-5955
3. Bates G.P., and Hockly E. Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?. Curr. Opin. Neurol. 16 (2003) 465-470
4. Bauer P.O., et al. Inhibition of rho-kinases enhances the degradation of mutant huntingtin. J. Biol. Chem. 284 (2009) 13153-13164
5. Burnett B.G., et al. Expression of expanded polyglutamine targets profilin for degradation and alters actin dynamics. Neurobiol. Dis. 30 (2008) 365-374
6. Chandra S., et al. A common motif targets huntingtin and the androgen receptor to the proteasome. J. Biol. Chem. 283 (2008) 23950-23955
7. Chen M., et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6 (2000) 797-801
8. Chopra V., et al. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 16685-16689
9. Chou S.Y., et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 93 (2005) 310-320
10. Davies S.W., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997) 537-548
11. Ferrante R.J., et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22 (2002) 1592-1599
12. Ferrante R.J., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23 (2003) 9418-9427
13. Ferrante R.J., et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J. Neurosci. 24 (2004) 10335-10342
14. Fox J.H., et al. Cystamine increases l-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J. Neurochem. 91 (2004) 413-422
15. Goehler H., et al. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol. Cell. 15 (2004) 853-865
16. Hockly E., et al. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 51 (2002) 235-242
17. Hockly E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2041-2046
18. Hockly E., et al. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain. Res. Bull. 61 (2003) 469-479
19. Inan S., and Buyukafsar K. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. Br. J. Pharmacol. 155 (2008) 44-51
20. Ishizaki T., et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 57 (2000) 976-983
21. Kazantsev A., et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat. Genet. 30 (2002) 367-376
22. Li M., et al. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J. Biol. Chem. 282 (2007) 3157-3164
23. Mangiarini L., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
24. Pattison J.S., and Robbins J. Protein misfolding and cardiac disease: establishing cause and effect. Autophagy 4 (2008) 821-823
25. Pollitt S.K., et al. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron 40 (2003) 685-694
26. Ravikumar B., and Rubinsztein D.C. Role of autophagy in the clearance of mutant huntingtin: a step towards therapy?. Mol. Aspects Med. 27 (2006) 520-527
27. Ravikumar B., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36 (2004) 585-595
28. Scherzinger E., et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90 (1997) 549-558
29. Shao J., and Diamond M.I. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet. 16 Spec No. 2 (2007) R115-R123
30. Shao J., et al. ROCK and PRK-2 mediate the inhibitory effect of Y-27632 on polyglutamine aggregation. FEBS Lett. 582 (2008) 1637-1642
31. Shao J., et al. Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol. Cell. Biol. 28 (2008) 5196-5208
32. Shibuya M., et al. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J. Neurol. Sci. 238 (2005) 31-39
33. Takahashi T., et al. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum. Mol. Genet. (2007)
34. Takahashi Y., et al. Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy. J. Biol. Chem. 282 (2007) 24039-24048
35. Tanaka M., et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10 (2004) 148-154
36. Uehata M., et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389 (1997) 990-994
37. Wang J.C., et al. Novel arylpyrazole compounds selectively modulate glucocorticoid receptor regulatory activity. Genes Dev. 20 (2006) 689-699
38. Zhang X., et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 892-897